Results 211 to 220 of about 31,387 (227)

EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma

Journal of Clinical Oncology, 2023
PURPOSE Patients with metastatic urothelial carcinoma have poor prognosis after failure of standard first-line chemotherapy. Immune check point programmed death 1-programmed death ligand 1 antibodies have low response rates and thus there exists a major unmet need.
Sarmad Sadeghi, David Quinn, Tanya Dorff, Sumanta Pal, Susan Groshen, Denice Tsao-Wei, Rahul Parikh, Michael Devitt, Mamta Parikh, Alexandra Jackovich, Nora Ruel, Nicholas Vogelzang, Earle Burgess, Imran Siddiqi, Inderbir S. Gill, Primo N. Lara, Robert Dreicer, Parkash S. Gill   +17 more
openaire   +2 more sources

Second-Line Therapies in Metastatic Urothelial Carcinoma

Hematology/Oncology Clinics of North America, 2015
Patients with relapsed or refractory urothelial carcinoma (UC) face a poor prognosis and a dearth of available treatment options that improve their survival. End-organ function and performance status play a vital role in the choice of second-line therapies.
Sujata, Narayanan, Lauren C, Harshman, Sandy, Srinivas   +2 more
openaire   +2 more sources

Clinical Trials in Metastatic Urothelial Carcinoma

2021
There have been major advances in metastatic urothelial carcinoma with the approval of five immune checkpoint inhibitors in platinum-refractory setting (two of them are also approved for cisplatin-ineligible patients as first-line therapy) and the recent FDA approval of avelumab as switch maintenance therapy after response or stable disease with ...
Vadim S. Koshkin, Petros Grivas
openaire   +1 more source

Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma

ONCOLOGY, 2023
A Hispanic man, aged 42 years, was diagnosed with stage IV metastatic urothelial bladder cancer (MUBC) with nonregional lymphadenopathies and lung, bone, and skin involvement. He received first-line treatment with gemcitabine and cisplatin for 6 cycles, achieving a partial response (PR).
Francisco Javier, Castro-Alonso, Evelyn, Beas-Lozano, Yuly A, Remolina-Bonilla, Thomas W, Flaig, María T, Bourlon   +4 more
openaire   +2 more sources

Avelumab in locally advanced or metastatic urothelial carcinoma

Expert Review of Anticancer Therapy, 2022
Outcomes for patients with advanced or metastatic urothelial carcinoma (UC) remain poor. Targeting the programmed death ligand-1 (PD-(L)1) immune checkpoint pathway has emerged as a useful target in patients with UC. Avelumab is a PD-L1 inhibitor, resulting in restoration of a cytotoxic, antitumor T cell response.
Francesca Jackson-Spence, Bernadett Szabados, Charlotte Toms, Yu-Hsuen Yang, Christopher Sng, Thomas Powles   +5 more
openaire   +2 more sources

Immunotherapy for metastatic urothelial carcinoma

Current Opinion in Urology, 2018
The treatment paradigm of urothelial carcinoma has been revolutionized by the advent of multiple anti-programmed-cell death-1/ligand-1 (PD-1/PD-L1) antibodies. Significant improvements have been obtained in the locally advanced or metastatic stage, which was lacking of therapeutic standards.
Necchi A, Rink M, Giannatempo P, Raggi D, Xylinas E   +4 more
openaire   +3 more sources

Genomic characterization of metastatic urothelial carcinoma.

Journal of Clinical Oncology, 2013
247 Background: The genetic profile of primary urothelial carcinoma (UC) has been well documented but no reports analyze specific chromosomal alterations in metastatic disease. We performed molecular inversion probe array (MIP) analysis to compare chromosomal gains or losses in metastatic and primary UC samples.
Richard M. Bambury, Markus Riester, Joaquim Bellmunt, Edward C. Stack, Lillian Werner, Rachel Park, Gopa Iyer, Massimo Loda, Philip W. Kantoff, Franziska Michor, Jonathan E. Rosenberg   +10 more
openaire   +1 more source

Venous thromboembolism in metastatic urothelial carcinoma.

Journal of Clinical Oncology, 2016
e16029Background: Cancer is established risk factor for development of venous thromboembolism (VTE).
Patrik Palacka, Jan Luha, Michal Mego, Viera Stvrtinova, Zuzana Sycova-Mila, Jana Obertova, Daniela Svetlovska, Katarina Rejlekova, Michal Chovanec, Jozef Mardiak   +9 more
openaire   +1 more source

The landscape of immunotherapy in metastatic urothelial carcinoma

Current Opinion in Urology, 2019
This review provides an overview of clinical trials recently completed or currently ongoing evaluating the role of checkpoint blockade in metastatic urothelial carcinoma.In 2016, five immunotherapy agents were approved for metastatic urothelial carcinoma patients who had progressed on platinum-based chemotherapy All five agents evinced an approximately
Min Yuen, Teo, Gopa, Iyer
openaire   +2 more sources

PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma

Clinical Genitourinary Cancer, 2020
Immune checkpoint inhibitors are now standard of care for many patients with metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC). Given real-world limitations in programmed death-ligand 1 (PD-L1) testing, concordance studies between PD-L1 assays are needed.
Landon C. Brown, Jason Zhu, Matthew K. Labriola, Yuan Wu, Sachica Cheris, Xin Liu, Kathryn Perkinson, Zuowei Su, Shannon McCall, Jiaoti Huang, Wen-Chi Foo, Rajan T. Gupta, Andrew J. Armstrong, Daniel J. George, Michael R. Harrison, Tian Zhang   +15 more
openaire   +2 more sources